Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappaB and induction of apoptosis

Oncogene

Volumn 23, Issue 14, 2004, Pages 2507-2522

  Gupta, Sanjay ^a   Hastak, Kedar ^b   Afaq, Farrukh ^c   Ahmad, Nihal ^c   Mukhtar, Hasan ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Apoptosis; Caspases; Epigallocatechin 3 gallate; Green tea; Nuclear factor kappa B

Indexed keywords

BENZYLOXYCARBONYLASPARTYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 3; CASPASE 3 INHIBITOR; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; DNA; EPIGALLOCATECHIN GALLATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROTECTION; CELL STRAIN; CONTROLLED STUDY; DNA STRAND BREAKAGE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INHIBITION KINETICS; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TRANSCRIPTION INITIATION;

AMINO ACID CHLOROMETHYL KETONES; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASPASES; CATECHIN; CELL LINE, TUMOR; CELL NUCLEUS; CELL SURVIVAL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; MALE; MODELS, BIOLOGICAL; NF-KAPPA B; OLIGOPEPTIDES; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; TIME FACTORS; TRANSCRIPTION, GENETIC;

EID: 1942532874     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207353     Document Type: Article

References (41)

1. Aggarwal BB. (2000). Biochem. Pharmacol., 60, 1033-1039.
2. Ahmad N, Feyes DK, Nieminen AL, Agarwal R and Mukhtar H. (1997). J. Natl. Cancer Inst., 89, 1881-1886.
3. Ahmad N, Gupta S and Mukhtar H. (2000). Arch. Biochem. Biophys., 376, 338-346.
4. Bours V, Bentires-Alj M, Hellin AC, Viatour P, Robe P, Delhalle S, Benoit V and Merville MP. (2000). Biochem. Pharmacol., 60, 1085-1089.
5. Chen ZP, Schell JB, Ho CT and Chen KY. (1998). Cancer Lett., 129, 173-179.
6. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K and Hardwick JM. (1997). Science, 278, 1966-1968.
7. Chung JH, Han JH, Hwang EJ, Seo JY, Cho KH, Kim KH, Youn JI and Eun HC. (2003). FASEB J., 17, 1913-1915.
8. Chung LY, Cheung TC, Kong SK, Fung KP, Choy YM, Chan ZY and Kwok TT. (2001). Life Sci., 68, 1207-1214.
9. Clem RJ, Cheng EH, Karp CL, Kirsch DG, Ueno K, Takahashi A, Kastan MB, Griffin DE, Earnshaw WC, Veliuona MA and Hardwick JM. (1998). Proc. Natl. Acad. Sci. USA, 95, 554-559.
10. Clement MV, Hirpara JL, Chawdhury SH and Pervaiz S. (1998). Blood, 92, 996-1002.
11. Ferreira CG, Epping M, Kruyt FA and Giaccone G. (2002). Clin. Cancer Res., 8, 2024-2034.
12. Green D and Kroemer G. (1998). Trends Cell Biol., 8, 267-271.
13. Grutter MG. (2000). Curr. Opin. Struct. Biol., 10, 649-655.
14. Gupta S, Ahmad N, Nieminen AL and Mukhtar H. (2000). Toxicol. Appl. Pharmacol., 164, 82-90.
15. Gupta S, Hussain T and Mukhtar H. (2003). Arch. Biochem. Biophys., 410, 177-185.
16. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML and Mukhtar H. (2003). Oncogene, 22, 4851-4859.
17. Hayakawa S, Saeki K, Sazuka M, Suzuki Y, Shoji Y, Ohta T, Kaji K, You A and Isemura M. (2001). Biochem. Biophys. Res. Commun., 285, 1102-1106.
18. Islam S, Islam N, Kermode T, Johnstone B, Mukhtar H, Moskowitz RW, Goldberg VM, Malemud CJ and Haqqi TM. (2000). Biochem. Biophys. Res. Commun., 270, 793-797.
19. Janicke RU, Walker PA, Lin XY and Porter AG. (1996). EMBO J., 15, 6969-6978.
20. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B and Pestell RG. (2001). Cytokine Growth Factor Rev., 12, 73-90.
21. Karin M and Lin A. (2002). Nat. Immunol., 3, 221-227.
22. Kim PK, Mahidhara R and Seol DW. (2001). Drug Resist. Updat., 4, 293-296.
23. Kong AN, Yu R, Hebbar V, Chen C, Owuor E, Hu R, Ee R and Mandlekar S. (2001). Mutat. Res., 480-481, 231-241.
24. Kuo PL and Lin CC. (2003). J. Biomed. Sci., 10, 219-227.
25. Lazebnik YA, Takahashi A, Moir RD, Goldman RD, Poirier GG, Kaufmann SH and Earnshaw WC. (1995). Proc. Natl. Acad. Sci. USA, 92, 9042-9046.
26. Levkau B, Scatena M, Giachelli CM, Ross R and Raines EW. (1999). Nat. Cell Biol., 1, 227-233.
27. Masuda M, Suzui M and Weinstein IB. (2001). Clin. Cancer Res., 7, 4220-4229.
28. Nicholson DW. (1999). Cell Death Differ., 6, 1028-1042.
29. Ravi R, Bedi A, Fuchs EJ and Bedi A. (1998). Cancer Res., 58, 882-886.
30. Schwartz SA, Hernandez A and Mark Evers B. (1999). Surg. Oncol., 8, 143-153.
31. Singh AK, Seth P, Anthony P, Husain MM, Madhavan S, Mukhtar H and Maheshwari RK. (2002). Arch. Biochem. Biophys., 401, 29-37.
32. Stennicke HR and Salvesen GS. (2000). Biochim. Biophys. Acta, 1477, 299-306.
33. Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK and Lee SS. (2001). Mutat. Res., 480-481, 243-268.
34. Tang D and Kidd VJ. (1998). J. Biol. Chem., 273, 28549-28552.
35. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM. (1995). Cell, 81, 801-809.
36. Wang C-Y, Mayo MW and Baldwin Jr AS. (1996). Science, 274, 784.
37. Wu M, Lee H, Bellas RE, Schauer SL, Arsura M, Katz D, FitzGerald MJ, Rothstein TL, Sherr DH and Sonenshein GE. (1996). EMBO J., 15, 4682-4690.
38. Yamamoto Y and Gaynor RB. (2001). J. Clin. Invest., 107, 135-142.
39. Yang GY, Liao J, Kim K, Yurkow EJ and Yang CS: (1998). Carcinogenesis, 19, 611-616.
40. Yu R, Mandlekar S, Harvey KJ, Ucker DS and Kong AN. (1998). Cancer Res., 58, 402-408.
41. Zimmermann KC, Bonzon C and Green DR. (2001). Pharmacol. Ther., 92, 57-70.